8-KEarnings & ResultsExhibits & Filings

AMGEN INC 8-K Report, Financial Results (Apr 27, 2021)

Filed April 27, 2021For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed an 8-K on April 27, 2021, to furnish a press release announcing its first-quarter 2021 financial results. The report details the company's financial performance for the three months ended March 31, 2021, and its financial position as of that date. A key aspect of the filing is the presentation of non-GAAP financial measures, which Amgen uses to provide investors with a more enhanced understanding of its ongoing business operations and facilitate comparisons across periods. These non-GAAP measures exclude items such as acquisition-related expenses, costs from cost-saving initiatives, and certain investment and legal-related items, which are considered to be outside the ordinary course of business or variable in nature. Furthermore, the company highlighted its updated non-GAAP policy, effective January 1, 2021, which now excludes gains and losses on investments in equity securities from its non-GAAP measures. Amgen explained this change is to improve comparability between periods, as increased investments in these companies have led to greater variability. Prior year (2020) non-GAAP figures have been restated to reflect this new policy. The report also introduces Free Cash Flow (FCF) as an additional liquidity measure. Investors should note that while these non-GAAP measures are provided for supplementary analysis, they are not substitutes for GAAP financials and are not incorporated into other SEC filings.

Key Highlights

  • 1Amgen reported its unaudited financial results for the first quarter ended March 31, 2021.
  • 2The company provided a reconciliation of its non-GAAP financial measures, including non-GAAP EPS, operating income, and net income, to their GAAP counterparts.
  • 3Key exclusions from non-GAAP measures include acquisition-related expenses, cost savings initiatives, and certain investment/legal items.
  • 4Amgen has updated its non-GAAP policy as of January 1, 2021, to exclude gains and losses on equity investments.
  • 5Prior year (2020) non-GAAP net income and EPS have been restated for comparability with the updated policy.
  • 6Free Cash Flow (FCF) was presented as an additional liquidity measure.
  • 7The information provided is furnished and not deemed 'filed' under Section 18 of the Exchange Act, nor incorporated into other SEC filings.

Frequently Asked Questions

The primary purpose of this 8-K filing is to furnish Amgen's press release announcing its unaudited financial results for the first quarter of 2021. It provides key financial performance indicators and an overview of the company's financial condition as of March 31, 2021.

Non-GAAP financial measures are financial metrics that exclude certain items from their corresponding GAAP (Generally Accepted Accounting Principles) figures. Amgen uses them to provide investors with a supplemental view of its ongoing business operations, allowing for better comparisons across different periods by excluding items that may be variable or not indicative of core business performance, such as acquisition-related costs or certain investment gains/losses.

Effective January 1, 2021, Amgen began excluding gains and losses on investments in equity securities from its non-GAAP measures. This change was implemented because increased investments in these companies led to greater variability, which could impede comparability between financial reporting periods. The company has also restated its 2020 non-GAAP results to align with this updated policy.

Free Cash Flow (FCF) is calculated by subtracting capital expenditures from cash flow from operating activities. Amgen presents FCF as an additional measure of its liquidity, offering insights into the cash generated from its operations that is available after accounting for investments in its assets.